CeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™ Series E Financing Reflects Sustained Investor Confidence in CeQur’s

Extended 7-Day Wear and 1-Unit Dosing Clearances, and Two ADA Posters Signal a New Standard for Mealtime Insulin Management CeQur®, the company dedicated to simplifying

CeQur announces that its wearable insulin patch, CeQur Simplicity™, has replaced 10 million mealtime insulin injections. The company continues its momentum with expanded clinical access and

The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams and outreach initiatives to bring CeQur Simplicity™, its

The CeQur Simplicity patch is now FDA-cleared for up to 4 days of wear. Each patch replaces up to 12 injections further simplifying mealtime insulin management.

CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the appointments of Rick Doubleday